Exhaled nitric oxide and asthma: complex interactions between atopy, airway responsiveness, and symptoms in a community population of children

P J Franklin, S W Turner, P N Le Souëf, S M Stick

Background: Exhaled nitric oxide (FE\textsubscript{NO}) is raised in asthmatic children, but there are inconsistencies in the relationship between FE\textsubscript{NO} and characteristics of asthma, including atopy, increased airway responsiveness (AR), and airway inflammation. The aim of this study was to investigate the relationship between FE\textsubscript{NO} and asthma, atopy, and increased AR in children.

Methods: One hundred and fifty five children (79 boys) of mean age 11.5 years underwent an assessment that included FE\textsubscript{NO} measurements, spirometric tests, inhaled histamine challenge, and a skin prick test. Blood was collected for eosinophil count. Current and past asthma like symptoms were determined by questionnaire.

Results: In multiple linear regression analyses FE\textsubscript{NO} was associated with atopy (p < 0.001), level of AR (p = 0.005), blood eosinophil count (p = 0.007), and height (p = 0.002) but not with physician diagnosed asthma (p = 0.1) or reported wheeze in the last 12 months (p = 0.5). Separate regression models were conducted for atopic and non-atopic children and associations between FE\textsubscript{NO} and AR, blood eosinophils and height were only evident in atopic children. Exhaled NO was raised in children with a combination of atopy and increased AR independent of symptoms.

Conclusion: Raised FE\textsubscript{NO} seems to be associated with an underlying mechanism linking atopy and AR but not necessarily respiratory symptoms.

Exhaled nitric oxide

Exhaled NO was measured using a fast response chemiluminescence analyser (NOA 280, Sievers Instruments Inc, Boulder, CO, USA) as previously described. Measurements
were taken before spirometry and histamine challenge. Children maintained an expiratory flow of 35 ml/s and mouth pressure of 15 cm H2O.

**Pulmonary function and airway responsiveness**
Pulmonary function testing was performed using a hand held spirometer (Pneumocheck Spirometer 6100; Welch-Allyn, Skaneateles Falls, NY, USA) in accordance with published guidelines. Airway responsiveness to histamine was determined using the rapid dosimeter technique. Responsiveness was expressed as the dose of histamine (μM) that provoked at least a 20% fall in FEV1 (PD20) and increased AR was defined as PD20 <7.8 μM histamine. A dose response slope (DRS) was also calculated using the method of O’Connor et al.

**Skin prick testing and eosinophil count**
Skin reactivity to cow’s milk, egg white, rye grass, mixed grass, *Dermatophagoides farinae*, *Dermatophagoides pteronyssinus*, cat dander, dog dander, *Alternaria alternans* and *Aspergillus fumigatus* (Hollister-Stier, Elkhart, IN, USA) was assessed by skin prick tests as described by Pepys. The positive control (0.9% saline). A positive skin prick test was defined as a weal at least 3 mm in its longest dimension. Atopy was defined as the presence of at least one positive skin prick test. Blood was collected and the eosinophil count was measured using a flow cytometer (Coulter Maxx, Beckman-Coulter Inc). Values are expressed as absolute cell counts.

**Statistical analyses**
Exhaled NO, DRS, and blood eosinophil values were skewed and were log10 transformed before analysis (a constant of 1 was added to DRS values) to achieve a near normal distribution. Associations between log(FENO) and reported physician diagnosed asthma, wheeze in the last 12 months (recent wheeze), current asthma (wheeze in the last 12 months plus increased AR), atopy, log(DRS), log(blood eosinophils), height, age, and spirometric variables were assessed in univariate analyses using Student’s t tests and simple linear regression. Multiple linear regression analyses were undertaken using transformed FENO values as the outcome variable which was computed by taking the antilog of the estimate of increase (or difference) in transformed FENO to give the fold increase per unit change in a continuous explanatory variable or fold difference between levels of a binary explanatory variable. Only factors that had a significance level of at least p ≤ 0.1 from univariate analyses were included in the model. These were age, height, log(eosinophil count), log(DRS), and atopy. Symptoms were included in the model separately as either reported physician diagnosed asthma or recent wheeze. Interactions between atopy and all other factors were investigated and separate regression models were constructed for both atopic and non-atopic children. Variables in all models were included in a stepwise fashion if they did not reach significance at the 5% level. Exhaled NO levels are reported as geometric means (GM) with 95% confidence intervals (CI). All analyses were performed using SPSS version 9.0 (SPSS, Chicago, IL, USA).

**RESULTS**
Exhaled NO concentrations were measured in 155 subjects (79 boys) of mean (SD) age 11.5 (2.3) years (range 6–18). There was no significant difference with regard to age, sex, height, atopic status, AR, FEV1, eosinophil count, physician diagnosed asthma, reported recent wheeze, and use of inhaled steroids between these children and those in whom FENO measurements were not made (n = 201).

Five children treated with regular inhaled corticosteroids (ICS) were excluded from analyses because of the known effects of ICS on FENO. Of the remaining 150 children, spirometric tests were performed in all individuals, skin prick testing in 149 (99%), bronchial challenge in 144 (96%), and eosinophil counts in 136 (91%). Eighty three children (56%) were atopic, 54 (38%) had increased AR, 34 (23%) reported wheeze in the past 12 months, and 26 (17%) had physician diagnosed asthma.

In univariate analyses, FENO was higher in children who had reported physician diagnosed asthma (16.4 ppb, 95% CI 11.0 to 24.6) than in non-asthmatic children (11.0 ppb, 95% CI 9.4 to 12.9; p < 0.03), in those with reported recent wheeze (16.6 ppb, 95% CI 11.9 to 23.2) than in those without recent wheeze (10.8 ppb, 95% CI 9.2 to 12.7; p = 0.01), and in those with current asthma (24.5 ppb, 95% CI 15.0 to 40.0) than in those without current asthma (11.0 ppb, 95% CI 9.5 to 12.8; p < 0.001). Atopic children (17.9 ppb, 95% CI 14.9 to 21.4) had significantly higher FENO levels than non-atopic children (7.2 ppb, 95% CI 6.0 to 8.7; p < 0.001) and there was a positive correlation between the number of skin prick reactions and FENO (Pearson’s correlation coefficient r = 0.61, p < 0.001).

There was a positive association between FENO and DRS (r2 = 0.21, p < 0.001), eosinophil count (r2 = 0.11, p < 0.001), and height (r2 = 0.05, p < 0.008). There were no associations between FENO and measurements of pulmonary function when adjusted for height. The relationship between FENO and DRS in atopic and non-atopic children is shown in fig 1.

In the multiple regression model atopy (p < 0.001), DRS (p = 0.003), eosinophil count (p = 0.003), and height (p = 0.002) were all significantly associated with FENO (table 1). Neither physician diagnosed asthma (p = 0.1) nor recent wheeze (p = 0.5) were associated with FENO in this model. There was a significant interaction between atopy and DRS (p = 0.001) and a trend for an interaction between atopy and eosinophil count (p = 0.06). In order to examine these interactions further, separate regression models were constructed for atopic and non-atopic children. In these models DRS, eosinophils, and height were associated with FENO in atopic (table 2) but not in non-atopic children (table 3). Again, neither physician diagnosed asthma nor recent wheeze were associated with FENO in either of these models.

**Figure 1** Relationship between FENO and airway responsiveness (DRS) in atopic (○) and non-atopic (●) children. Separate regression lines for atopic and non-atopic children are included. Only in atopic children is there a significant relationship between FENO and DRS (r2 = 0.301, p < 0.001).
As there were a number of sibling pairs in this cohort, there may be genetic linkage within the group. The children from the original cohort (n = 97) were therefore analysed separately and the observed associations persisted.

**Receiver operator characteristics curve**

As FENO was found to be associated with AR only in atopic children and was independent of symptoms, we hypothesised that FENO may provide a simple test to identify atopic children with increased AR. This was investigated by generating a receiver operator characteristic (ROC) curve to determine the specificity and sensitivity of FENO for predicting increased AR in atopic children (fig 2). For this analysis, increased AR was defined as PD20 <7.8 μM.24 A level of 18.4 ppb was identified as giving the best combination of sensitivity and specificity (81.1% and 78.6%). The likelihood ratio for an atopic child in our population having FENO of <18.4 ppb and increased AR is only 0.23. Height, which was associated with FENO in this study, contributed to the variability of the sensitivity and specificity such that individuals below the average height tend to reduce the sensitivity and individuals with above average height tend to reduce the specificity.

**DISCUSSION**

This study has shown that atopy modifies the association between FENO and both AR and blood eosinophil counts. An important finding is that FENO is raised in children with a combination of both atopy and increased AR, and this was independent of symptoms. Interestingly, FENO was not raised in subjects with only atopy or increased AR. These data suggest that raised FENO levels are the result of a mechanism(s) linking increased AR and atopy and extend the recently published observations of Steerenberg et al.24

We have previously reported an association between raised FENO and positive skin prick reactions in healthy children.24 The association between increased FENO and atopy in healthy subjects has been confirmed in other studies,25 but it is not a universal finding.25 Similarly, the data regarding the association between FENO and AR have been inconclusive.26 27 The results of this study extend our earlier observations and help to explain some inconsistencies in reported data. Our observations also explain the consistent reports of raised FENO levels in atopic compared with non-atopic asthmatics.11 15

A major finding from both our study and a recent study by Steerenberg et al24 is that the relationship between FENO and AR is only evident in atopic children. Ludviksdottir and colleagues11 reported a similar relationship in asthmatic adults. There is a well established relationship between atopy and increased AR in both children28 29 and adults,11 12 and our data suggest that increased NO production in the airways may be associated with a mechanism linking these two factors. This may involve inflammatory processes and would support the hypothesis that FENO is a marker of allergic airway inflammation. Peat et al16 suggested that IgE mediated inflammatory reactions in the airways of atopic children could lead to increased AR. We found that there was a relationship between FENO and blood eosinophils which was also dependent on the presence of atopy. This relationship has also been reported in an unselected population of children,17 as well as in a group of asthmatic children.29 In our study there was a positive correlation between peripheral eosinophils and DRS in the atopic but not the non-atopic children (data not shown). Blood eosinophils, however, do not necessarily reflect inflammatory processes in the lungs,29 and an alternative explanation is that increased FENO in this phenotype may be due to genetic variations in NO synthase (NOS) genes. In patients with asthma30 and cystic fibrosis,31 variations in FENO are associated with a polymorphism in the NOS1 gene. The NOS1 isoform has been shown to be important in the regulation of AR in animal models.32 Further investigations are required to determine the contribution of the various NOS isoform(s) to NO production in the airways of children with atopy and increased AR.

Interestingly, we found that the association between FENO and atopy and increased AR was independent of symptoms. This was a representative population sample of asthmatic children, although children with more severe asthma (those taking ICS) were excluded because of the known effects of ICS on FENO. Our findings are in agreement with those of Leuppi et al29 who found significantly raised FENO levels in

---

**Table 1** Fold difference in fractional exhaled nitric oxide (FENO) in children with symptoms compared with children without symptoms, and fold increase per unit change in log(eosinophils), log(DRS), and height in study population (n = 150)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Fold difference/increase</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopy</td>
<td>1.83</td>
<td>1.39 to 2.41</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PDA</td>
<td>1.36</td>
<td>0.94 to 1.95</td>
<td>0.10</td>
</tr>
<tr>
<td>Recent wheeze</td>
<td>1.10</td>
<td>0.81 to 1.51</td>
<td>0.53</td>
</tr>
<tr>
<td>Eosinophils (per log unit)</td>
<td>1.94</td>
<td>1.26 to 3.00</td>
<td>0.003</td>
</tr>
<tr>
<td>DRS (per log unit)</td>
<td>1.88</td>
<td>1.25 to 2.86</td>
<td>0.003</td>
</tr>
<tr>
<td>Height (per cm)</td>
<td>1.02</td>
<td>1.01 to 1.03</td>
<td>0.002</td>
</tr>
</tbody>
</table>

PDA = physician diagnosed asthma; DRS = dose response slope.

**Table 2** Fold difference in fractional exhaled nitric oxide (FENO) in children with symptoms compared with children without symptoms, and fold increase per unit change in log(eosinophils), log(DRS), and height in atopic children (n = 80)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Fold difference/increase</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDA</td>
<td>1.18</td>
<td>0.79 to 1.75</td>
<td>0.40</td>
</tr>
<tr>
<td>Recent wheeze</td>
<td>1.09</td>
<td>0.76 to 1.57</td>
<td>0.62</td>
</tr>
<tr>
<td>Eosinophils (per log unit)</td>
<td>2.24</td>
<td>1.22 to 4.06</td>
<td>0.01</td>
</tr>
<tr>
<td>DRS (per log unit)</td>
<td>2.38</td>
<td>1.46 to 3.94</td>
<td>0.001</td>
</tr>
<tr>
<td>Height (per cm)</td>
<td>1.015</td>
<td>1.003 to 1.03</td>
<td>0.017</td>
</tr>
</tbody>
</table>

PDA = physician diagnosed asthma; DRS = dose response slope.
Exhaled NO and asthma

Atopic children with increased AR, regardless of symptoms. These authors suggested that FE\textsubscript{NO} may be more closely associated with increased AR than symptoms. In contrast, Henriksen et al\textsuperscript{13} found that suspected asthmatic adolescents with both atopy and increased AR had higher FE\textsubscript{NO} levels than healthy subjects with a similar phenotype. Similarly, Steerenberg et al\textsuperscript{14} found that FE\textsubscript{NO} was associated with respiratory symptoms in atopic children, but it appears that these authors might not have controlled for AR when investigating the association between FE\textsubscript{NO} and symptoms. Our results, if confirmed in future studies, suggest that raised FE\textsubscript{NO} levels in children are associated with a common asthma phenotype (that is, atopy and increased AR) but not with asthma per se.

Our observation that FE\textsubscript{NO} is raised in healthy children with both atopy and increased AR raises an intriguing possibility that NO might be protective in these children who are at risk of asthma but who have not developed symptoms. Indeed, there have been suggestions that NO may have a bronchodilator role through its actions on smooth muscle relaxation and inhibition of smooth muscle proliferation.\textsuperscript{35} Alternatively, raised FE\textsubscript{NO} may identify children who have latent asthma and are at risk of developing symptoms. Both atopy and increased AR in childhood have been reported as risk factors for the subsequent development of asthma in early adulthood.\textsuperscript{36} However, atopy and increased AR can coexist in adults in the absence of symptoms.\textsuperscript{27} The association between raised FE\textsubscript{NO} levels and the development of asthma later in life can only be addressed by longitudinal data. This cohort will be reassessed 5 years after the present data were obtained.

There has been considerable interest in FE\textsubscript{NO} as a diagnostic tool for asthma. A number of studies have reported good sensitivity and specificity of raised FE\textsubscript{NO} for discriminating between asthmatics and non-asthmatics.\textsuperscript{37–40} In each of these studies the asthmatic patients had increased AR or significant airways reversibility while the non-asthmatics all responded normally. No study has investigated the diagnostic value of FE\textsubscript{NO} in an unselected population. On the basis of our results we propose that low levels of FE\textsubscript{NO} may be useful to exclude increased AR in atopic children with symptoms and, therefore, to help to exclude a diagnosis of asthma. Increased AR is almost ubiquitous in clinically obvious asthma and most asthmatic children are atopic.\textsuperscript{21}

Tests of AR are not feasible in most clinical situations, particularly in children. Our data suggest that atopic children with respiratory symptoms but low FE\textsubscript{NO} levels are unlikely to have increased AR. Indeed, in our study, if FE\textsubscript{NO} levels are less than 18.4 ppb, the likelihood ratio for atopic children to have increased AR is only 0.23. We suggest that the diagnostic value of low FE\textsubscript{NO} levels could be further tested in a prospective study.

We have used an expiratory flow rate of 35 ml/s for measuring FE\textsubscript{NO}. The study was started before publication of recommendations for the measurement of FE\textsubscript{NO} in children.\textsuperscript{40} However, the marginally lower expiratory flow rate than that suggested in these guidelines used in our study is unlikely to affect our findings since Kissoon et al\textsuperscript{41} have reported that flow rates between 30 and 50 ml/s are appropriate for children. Indeed, the use of a low flow rate may have increased our ability to measure differences in FE\textsubscript{NO} between groups. Deykin et al\textsuperscript{42} showed in adults using higher flow rates that the discriminatory power of FE\textsubscript{NO} for differentiating between asthmatic and non-asthmatic subjects was not affected by expiratory flow rates ranging from 47 ml/s to 500 ml/s.

In summary, we have shown that atopy is important in the relationship between FE\textsubscript{NO} and AR. In this study, FE\textsubscript{NO} was associated with increased AR only in atopic children. Furthermore, there was an association between FE\textsubscript{NO} and blood eosinophils that was also only evident in atopic children. This supports the concept that FE\textsubscript{NO} reflects allergic airway inflammation and this may be one of the mechanisms explaining the relationship between atopy and AR. Alternatively, raised FE\textsubscript{NO} levels in children with both atopy and increased AR may be due to variations in NOS genes. This needs to be explored further. Raised FE\textsubscript{NO} levels in non-asthmatic atopic children with increased AR may either be predictive for the development of asthma or may indicate a protective role of NO against the development of symptoms. These issues will be addressed in the next follow up study of this population of children. After controlling for both atopy and increased AR, we were unable to show an association between FE\textsubscript{NO} and asthma or asthma like symptoms. This suggests that raised FE\textsubscript{NO} levels in children are associated with a common asthma phenotype but not with asthma per se. These results have implications for the use of FE\textsubscript{NO} as a diagnostic tool for asthma. However, we have proposed a role for FE\textsubscript{NO} in atopic children with symptoms of unknown aetiology to exclude increased AR and, by inference, to help to exclude asthma.

### Table 3

<table>
<thead>
<tr>
<th>Variable</th>
<th>Fold difference/increase</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDA</td>
<td>1.95</td>
<td>0.82 to 4.48</td>
<td>0.13</td>
</tr>
<tr>
<td>Recent wheeze</td>
<td>1.04</td>
<td>0.57 to 1.90</td>
<td>0.14</td>
</tr>
<tr>
<td>Eosinophils (per log unit)</td>
<td>1.52</td>
<td>0.81 to 2.86</td>
<td>0.19</td>
</tr>
<tr>
<td>DRS (per log unit)</td>
<td>0.92</td>
<td>0.41 to 2.07</td>
<td>0.84</td>
</tr>
<tr>
<td>Height (per cm)</td>
<td>1.00</td>
<td>0.99 to 1.03</td>
<td>0.15</td>
</tr>
</tbody>
</table>

PDA = physician diagnosed asthma; DRS = dose response slope.

![Figure 2](image-url)  
**Figure 2** ROC curve indicating the sensitivity and specificity for predicting increased AR in atopic children. Sensitivity and specificity were 81.1% and 78.6%, respectively, for an FE\textsubscript{NO} level of 18.4 ppb.
ACKNOWLEDGEMENTS
The authors would like to express their gratitude to study members and their parents for participating in this project.

Authors’ affiliations
P J Franklin, S W Turner, S M Stick, Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Australia
P J Franklin, S W Turner, P N Le Souef, University Department of Paediatrics, Princess Margaret Hospital for Children, Perth, Australia

Dr Turner was supported by the NH&MRC. Dr Franklin and Dr Stick are supported by the NH&MRC.

REFERENCES
Exhaled nitric oxide and asthma: complex interactions between atopy, airway responsiveness, and symptoms in a community population of children

P J Franklin, S W Turner, P N Le Souëf and S M Stick

Thorax 2003 58: 1048-1052
doi: 10.1136/thorax.58.12.1048

Updated information and services can be found at:
http://thorax.bmj.com/content/58/12/1048

These include:

References
This article cites 40 articles, 11 of which you can access for free at:
http://thorax.bmj.com/content/58/12/1048#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Child health (843)
Asthma (1782)
Inflammation (1020)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/